Trigeminal neuralgia (also called tic douloureux) is sometimes a symptom of multiple sclerosis and is often extremely painful. It tends to come and go unpredictably in sudden shock-like attacks that usually affect one side of the face.
Initial treatment is with drugs and people are often advised to avoid any triggers that set the pain off. Sometimes surgery is used if drugs do not work. However, surgery can leave the face feeling numb because it works by damaging the trigeminal nerve in the face.
This study looked at a particular kind of surgery called percutaneous balloon compression (PBC). A needle is inserted under local anaesthetic and a small balloon is used to compress the nerve. The resulting damage stops the electrical activity in the nerve which reduces or stops the pain.
The cases of 21 people with MS who had already received PBC for trigeminal neuralgia were reviewed. All had either an excellent or a good outcome with a single or repeated procedure. The factors which helped most were having only one branch of the trigeminal nerve affected, not having had previous surgery and using a short compression time and/or a pear-shaped balloon during the procedure.
The researchers concluded that PBC is a safe and effective treatment for trigeminal neuralgia when drug treatments have not worked.
Montano N, Papacci F, Cioni B, et al.
Percutaneous balloon compression for the treatment of trigeminal neuralgia in patients with multiple sclerosis.
Acta Neurochir (Wien). 2012 Feb 22. [Epub ahead of print]
You can read more about trigeminal neuralgia in the A-Z of MS.
Research by topic areas...
Symptoms and symptom management
Rotstein D, O'Connor P, Lee L, et al.
Multiple sclerosis fatigue is associated with reduced psychomotor vigilance.
Can J Neurol Sci. 2012 Mar;39(2):180-4.
Erb K, Bohner G, Harms L, et al.
Olfactory function in patients with multiple sclerosis: a diffusion tensor imaging study.
J Neurol Sci. 2012 Feb 16. [Epub ahead of print]
Falah M, Madsen C, Holbech JV, et al.
A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis.
Eur J Pain. 2011 Dec 19. doi: 10.1002/j.1532-2149.2011.00073.x. [Epub ahead of print]
Drugs in development
Gorman MP, Tillema JM, Ciliax AM, et al.
Daclizumab use in patients with pediatric multiple sclerosis.
Arch Neurol. 2012 Jan;69(1):78-81.
Bensmail D, Marquer A, Roche N, et al.
Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters.
Arch Phys Med Rehabil. 2012 Jan;93(1):96-9.
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
Expert Opin Drug Saf. 2011 Sep;10(5):675-85.
Walker LA, Berard JA, Berrigan LI, et al.
Detecting cognitive fatigue in multiple sclerosis: Method matters.
J Neurol Sci. 2012 Feb 13. [Epub ahead of print]
Quality of life
Patten SB, Williams JV, Lavorato DH, et al.
Health status, stress and life satisfaction in a community population with MS.
Can J Neurol Sci. 2012 Mar;39(2):206-12.
Sitjà Rabert M, Rigau Comas D, Fort Vanmeerhaeghe A, et al.
Whole-body vibration training for patients with neurodegenerative disease.
Cochrane Database Syst Rev. 2012 Feb 15;2:CD009097.
Motl RW, Smith DC, Elliott J, et al.
Combined training improves walking mobility in persons with significant disability from multiple sclerosis: a pilot study.
J Neurol Phys Ther. 2012 Feb 13. [Epub ahead of print]
Other demyelinating conditions
Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, et al.
Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study.
J Neurol. 2012 Feb 17. [Epub ahead of print]
Haacke EM, Beggs CB, Habib C.
The role of venous abnormalities in neurological disease.
Rev Recent Clin Trials. 2012 Feb 1. [Epub ahead of print]
Machine learning identifies new subtypes of MS from MRI scans
13 May 2021 - 00:00
Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.
Ozanimod (Zeposia) - NICE says no in final decision
13 May 2021 - 00:00
The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 Apr 2021 - 00:00
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.